Home › Breast Cancer › Indiana › Indianapolis
Breast Cancer clinical trials in Indianapolis, IN
20 studies for Breast Cancer are looking for participants at sites in and around Indianapolis (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
RecruitingPhase 3
- Investigative Clinical R of Indiana, Indianapolis
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RecruitingPhase 1
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
RecruitingPhase 2Healthy volunteers welcome
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RecruitingPhase 1/2
- Community Health Network, Indianapolis
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RecruitingPhase 3
- Franciscan Health ( Site 0077), Indianapolis
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Recruiting
- Indiana University, Indianapolis
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
RecruitingPhase 3
- Indiana University Health University Hospital, Indianapolis
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
RecruitingPhase 2
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RecruitingPhase 1
- Indiana University (IU) School of Medicine, Indianapolis
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
RecruitingPhase 3
- Community Health Network, Inc, Indianapolis
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
RecruitingPhase 2
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
- Sidney and Lois Eskenazi Hospital, Indianapolis
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
RecruitingPhase 3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Sidney and Lois Eskenazi Hospital, Indianapolis
- Community Cancer Center East, Indianapolis
- and 5 more
HER2 Vaccine for Locally Advanced Breast Cancer
RecruitingPhase 1
- Indiana University Melvin & Bren Simon Comprehensive Cancer Center, Indianapolis
Exercise in Metastatic Breast Cancer: EMBody
Recruiting
- Indiana University Melvin & Bren Simon Cancer Center, Indianapolis
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
RecruitingPhase 3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Franciscan Health Indianapolis, Indianapolis
- Franciscan Health Mooresville, Mooresville · 16 mi away
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
RecruitingPhase 2
- Indiana University, Indianapolis
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
RecruitingPhase 1/2
- Research Site, Indianapolis
NearWave Optical Molecular Monitoring
Recruiting
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
RecruitingPhase 3
- Franciscan Health Indianapolis, Indianapolis
- Franciscan Health Mooresville, Mooresville · 16 mi away
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
RecruitingPhase 1
- Community Health Network, Indianapolis
About Breast Cancer
Breast cancer is a cancer that starts in the breast tissue, when cells change and grow out of control. These extra cells can form a mass called a tumor.
More about Breast Cancer on MedlinePlus
Breast Cancer trials in other cities
- New York City, NY134 studies
- Houston, TX126 studies
- Boston, MA111 studies
- Nashville, TN80 studies
- Los Angeles, CA72 studies
- Edison, NJ68 studies
- St. Louis, MO64 studies
- Durham, NC63 studies
- Queens, NY63 studies
- Chicago, IL58 studies
- Philadelphia, PA56 studies
- Dallas, TX55 studies
Other studies in Indianapolis
- Non-Small Cell Lung Cancer32 studies
- Cancer (all types)24 studies
- Heart Failure23 studies
- Obesity20 studies
- Metastatic Cancer19 studies
- Colorectal Cancer18 studies
- Ovarian Cancer17 studies
- Lung Cancer16 studies
- Cardiovascular Disease16 studies
- Type 1 Diabetes14 studies
- Endometrial Cancer14 studies
- Alzheimer's Disease14 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.